论文部分内容阅读
目的研究胶质瘤干细胞标志物CD133、SSEA-1和Nestin在胶质瘤组织中表达及其与病理分级的相关性;探讨三者在人脑胶质瘤的诊断及恶性程度判断中的临床意义。方法应用免疫组织化学方法检测54例脑胶质瘤组织和6例正常脑组织标本中CD133、SSEA-1及Nestin的表达。结果 CD133、SSEA-1和Nestin在胶质瘤组织中的阳性细胞平均表达率分别为25.38%、26.62%和22.39%,而在正常脑组织中均无表达。CD133、SSEA-1和Nestin阳性细胞率在胶质瘤各病理级别间比较,差异均有统计学意义,且三者的表达与胶质瘤病理级别呈正相关(P<0.05)。SSEA-1与CD133、CD133与Nestin及SSEA-1与Nestin阳性细胞表达均呈正相关(P<0.05)。结论检测CD133、SSEA-1、Nestin表达,有利于胶质瘤的诊断及恶性程度判断,并在胶质瘤的个性化综合治疗和预后评估发挥作用。
Objective To study the expression of glioma stem cell markers CD133, SSEA-1 and Nestin in glioma tissue and its correlation with pathological grade. To explore the clinical significance of glioma diagnosis and malignancy in gliomas . Methods Immunohistochemistry was used to detect the expression of CD133, SSEA-1 and Nestin in 54 glioma tissues and 6 normal brain tissues. Results The average expression rates of CD133, SSEA-1 and Nestin in glioma tissue were 25.38%, 26.62% and 22.39%, respectively, but not in normal brain tissue. The positive rate of CD133, SSEA-1 and Nestin in gliomas was significantly higher than that in gliomas (P <0.05). There was a significant difference between the two groups in the pathological grades of gliomas. The positive expression of SSEA-1 and CD133, CD133 and Nestin, SSEA-1 and Nestin positive cells were positively correlated (P <0.05). Conclusion The detection of CD133, SSEA-1 and Nestin expression is beneficial to the diagnosis and malignant degree of gliomas, and plays an important role in the personalized comprehensive treatment of gliomas and prognosis.